# Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

Study · id `cardio:ct-nct01522417` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01522417](<https://clinicaltrials.gov/study/NCT01522417>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01522417

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 535 participants.

## Technical summary

Registry record NCT01522417. Randomized; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2018-12 (actual). Results posted on 2021-04-20.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 535 participants (enrolled count; ClinicalTrials.gov record NCT01522417, source copy `cardio:ctgov-nct01522417-2021-05-13`, retrieved 2026-10-26)
- Start date: 2012-04 (registry gives no type) (ClinicalTrials.gov record NCT01522417, source copy `cardio:ctgov-nct01522417-2021-05-13`, retrieved 2026-10-26)
- Primary completion: 2018-12 (actual) (ClinicalTrials.gov record NCT01522417, source copy `cardio:ctgov-nct01522417-2021-05-13`, retrieved 2026-10-26)
- Completion: 2019-03 (actual) (ClinicalTrials.gov record NCT01522417, source copy `cardio:ctgov-nct01522417-2021-05-13`, retrieved 2026-10-26)
- Results first posted: 2021-04-20 (ClinicalTrials.gov record NCT01522417, source copy `cardio:ctgov-nct01522417-2021-05-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01522417, source copy `cardio:ctgov-nct01522417-2021-05-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01522417-2021-05-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
- Acronym: SAVI-PCI
- Condition: Myocardial Infarction
- Condition: Acute Coronary Syndromes
- Condition: Unstable Angina
- Intervention (Drug): Short Tirofiban
- Intervention (Drug): Eptifibatide
- Intervention (Drug): Long Tirofiban
- Lead sponsor: Medicure
- Lead sponsor class: INDUSTRY
- Collaborator: SCRI Development Innovations, LLC
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)

## Provenance

Content hash: b4cb949dec44d132db3f206b56c945eb28fbe2592365a5229f156f97efe09774
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
